ImmunoGen Announces Webcast of Presentation and Q&A at the 38th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Jan 3, 2020--
ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 38 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation is scheduled for 9:30am PT (12:30pm ET) on January 16, 2020.
Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen’s management team for a question-and-answer session at 10:00am PT (1:00pm ET).
A webcast of the presentation and question-and-answer session will be accessible live through the “Investors & Media” section of the Company’s website, www.immunogen.com; a replay will be available in the same location.
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200102005091/en/
CONTACT: INVESTOR RELATIONS AND MEDIA
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY
SOURCE: ImmunoGen Inc.
Copyright Business Wire 2020.
PUB: 01/03/2020 10:46 AM/DISC: 01/03/2020 10:46 AM